{"id":"NCT02579759","sponsor":"Pharnext S.C.A.","briefTitle":"Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)","officialTitle":"International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2018-03","completion":"2018-08","firstPosted":"2015-10-20","resultsPosted":"2020-02-27","lastUpdate":"2020-02-27"},"enrollment":323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Charcot-Marie-Tooth Disease Type 1A"],"interventions":[{"type":"DRUG","name":"PXT3003 dose 1","otherNames":["DOSE 1"]},{"type":"DRUG","name":"PXT3003 dose 2","otherNames":["DOSE 2"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"PXT3003 dose 1","type":"ACTIVE_COMPARATOR"},{"label":"PXT3003 dose 2","type":"ACTIVE_COMPARATOR"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A). This double-blind study will assess in parallel groups 2 doses of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.","primaryOutcome":{"measure":"Overall Neuropathy Limitation Scale (ONLS) Total Score","timeFrame":"From Baseline to Month 15","effectByArm":[{"arm":"PXT3003 Dose 1","deltaMin":3.33,"sd":1.05},{"arm":"PXT3003 Dose 2","deltaMin":3.05,"sd":1.13},{"arm":"Placebo","deltaMin":3.23,"sd":1.19}],"pValues":[{"comp":"OG001 vs OG002","p":"0.008"},{"comp":"OG000 vs OG002","p":"0.287"},{"comp":"OG001 vs OG002","p":"0.013"},{"comp":"OG000 vs OG002","p":"0.05"},{"comp":"OG000 vs OG001 vs OG002","p":"0.013"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":30,"countries":["United States","Belgium","Canada","France","Germany","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["25519680","25491744","26070802","30650121","27387831"],"seeAlso":["https://www.ncbi.nlm.nih.gov/pubmed/25519680","https://www.ncbi.nlm.nih.gov/pubmed/?term=25491744","https://www.ncbi.nlm.nih.gov/pubmed/?term=26070802","https://www.ncbi.nlm.nih.gov/pubmed/?term=30650121","https://www.ncbi.nlm.nih.gov/pubmed/?term=27387831","https://www.emjreviews.com/neurology/abstract/baclofen-naltrexone-and-sorbitol-all-contribute-to-the-efficacy-of-pxt3003-in-cmt1a-rats/"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":109},"commonTop":["Nasopharyngitis","Headache","Nausea","Arthralgia","Pain in extremity"]}}